azd-2516
Small moleculeexperimental
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2008 (NCT00754715)
Timeline
Indications
Mechanism of action
- Metabotropic glutamate receptor 5NEGATIVE ALLOSTERIC MODULATOR
GRM5 negative allosteric modulator
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545346 ↗
Also known as
- azd2516
- azd2516
- azd-2516
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01148095 | Phase 1 | Jun 1, 2010 | AstraZeneca, IQVIA |
| NCT01154634 | Phase 2 | May 1, 2010 | AstraZeneca |
| NCT00972049 | Phase 1 | Sep 1, 2009 | AstraZeneca, Kyushu Clinical Pharmacolgy Reasearch Clinic |
| NCT00892944 | Phase 1 | Apr 1, 2009 | AstraZeneca |
| NCT00754715 | Phase 1 | Sep 1, 2008 | AstraZeneca |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 5 | 5 | 2 | 2008 |
| IQVIA | For profit | 1 | 0 | 1 | 2010 |
| Kyushu Clinical Pharmacolgy Reasearch Clinic | Academic/Hospital | 1 | 0 | 1 | 2009 |
3 organizations
Page 1 / 1